Argos Therapeutics (ARGS) Earning Somewhat Positive Media Coverage, Analysis Finds
Headlines about Argos Therapeutics (NASDAQ:ARGS) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Argos Therapeutics earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.8098730810264 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news articles that may have effected Accern’s rankings:
- Argos Therapeutics, Inc. (ARGS) Downgraded to Sell at Zacks Investment Research (americanbankingnews.com)
- At This Price, Is It Too Late To Buy Argos Therapeutics, Inc. (ARGS)? – AllStockNews (allstocknews.com)
- Chartists Place Argos Therapeutics Inc (ARGS) on Notice: Technical Update – Evergreen Caller (evergreencaller.com)
- Is Argos Therapeutics, Inc. (NASDAQ:ARGS) a Bargain? Update on The Stock – FLBC News (flbcnews.com)
- Comparing BioMarin Pharmaceutical (BMRN) and Argos Therapeutics (NASDAQ:ARGS) (americanbankingnews.com)
Shares of Argos Therapeutics (ARGS) opened at 0.2388 on Tuesday. Argos Therapeutics has a 52-week low of $0.23 and a 52-week high of $5.68. The firm has a 50-day moving average price of $0.30 and a 200-day moving average price of $1.04. The stock’s market cap is $9.87 million.
Argos Therapeutics (NASDAQ:ARGS) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.01. The business had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.10 million. Argos Therapeutics had a negative return on equity of 1,442.99% and a negative net margin of 12,391.15%. On average, analysts anticipate that Argos Therapeutics will post ($1.14) EPS for the current fiscal year.
A number of research firms have commented on ARGS. Zacks Investment Research downgraded Argos Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday. FBR & Co reduced their target price on Argos Therapeutics from $2.00 to $1.20 and set a “mkt perform” rating on the stock in a research report on Wednesday, April 19th. One analyst has rated the stock with a sell rating and three have given a hold rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $3.23.
About Argos Therapeutics
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.